Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Theravectys S.A.
DescriptionVaccine contaning 2 lentiviral vectors derived from 4 proteins in the human T-Cell lymphotropic virus type 1 (HTLV-1) virus
Molecular Target
Mechanism of ActionVaccine
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentPreclinical
Standard IndicationHematologic malignancies
Indication DetailsTreat adult T cell leukemia and lymphoma
Regulatory Designation EU - Orphan Drug (Treat adult T cell leukemia and lymphoma)

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today